Your browser doesn't support javascript.
loading
Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study.
Deng, Lijuan; Li, Zhiming; Zhang, Huilai; Huang, Haiwen; Hu, Jianda; Liu, Lihong; Liu, Ting; Jin, Jie; Zhu, Zunmin; Li, Wenyu; Huang, Zhenqian; Huang, Wenrong; Zhou, Keshu; Yang, Haiyan; Zhang, Mingzhi; Ding, Kaiyang; Zhou, Hui; Hu, Yu; Shuang, Yuerong; Cao, Junning; Gao, Sujun; Li, Dengju; Sun, Zimin; Zhang, Qingyuan; Yi, Shuhua; Ji, Chunyan; Zhang, Liansheng; Hou, Cheng; Du, Yue; Wang, Weige; Zhao, Renbin; Song, Yuqin; Zhu, Jun.
Afiliación
  • Deng L; Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
  • Li Z; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Zhang H; Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
  • Huang H; Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Hu J; Department of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
  • Liu L; Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
  • Liu T; Department of Hematology, West China Hospital, Sichuan University, Chengdu, China.
  • Jin J; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Zhu Z; Department of Hematology, Henan Provincial People's Hospital, Zhengzhou, China.
  • Li W; Department of Lymphoma, Guangdong Provincial People's Hospital, Guangzhou, China.
  • Huang Z; Department of Hematology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Huang W; Department of Hematology, The Fifth Medical Center of the Chinese People's Liberation Army General Hospital, Beijing, China.
  • Zhou K; Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
  • Yang H; Department of Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
  • Zhang M; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Ding K; Department of Hematological Oncology, Anhui Province Cancer Hospital, Hefei, China.
  • Zhou H; Department of Lymphoma and Hematology, Hunan Cancer Hospital, Changsha, China.
  • Hu Y; Department of Hematology, Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China.
  • Shuang Y; Department of Hematology and Lymphoma, Jiangxi Cancer Hospital, Nanchang, China.
  • Cao J; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Gao S; Department of Hematology, The First Hospital of Jilin University, Changchun, China.
  • Li D; Department of Hematology, Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China.
  • Sun Z; Department of Hematology, Anhui Provincial Hospital, Hefei, China.
  • Zhang Q; Department of Internal Medicine-Oncology, Cancer Hospital of Harbin Medical University, Harbin, China.
  • Yi S; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
  • Ji C; Department of Oncology Medicine, Qilu Hospital of Shandong University, Jinan, China.
  • Zhang L; Department of Oncology Medicine, Lanzhou University Second Hospital, Lanzhou, China.
  • Hou C; Beijing InnoCare Pharma Tech Co., Ltd., Beijing, China.
  • Du Y; Beijing InnoCare Pharma Tech Co., Ltd., Beijing, China.
  • Wang W; Beijing InnoCare Pharma Tech Co., Ltd., Beijing, China.
  • Zhao R; Beijing InnoCare Pharma Tech Co., Ltd., Beijing, China.
  • Song Y; Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
  • Zhu J; Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
Am J Hematol ; 98(11): 1742-1750, 2023 Nov.
Article en En | MEDLINE | ID: mdl-37647123
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Am J Hematol Año: 2023 Tipo del documento: Article País de afiliación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Am J Hematol Año: 2023 Tipo del documento: Article País de afiliación: China